Pulsed Field Ablation During Left Atrial Appendage Occlusion: A Randomised Controlled Trial
Key facts
- Who runs it
- Liverpool Heart and Chest Hospital NHS Foundation Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Apr 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Catheter ablation of atrial fibrillation using Pulsed Field Ablation
- Left atrial appendage occlusion
- Record updated
- 19 July 2024
- Why it stopped
- Decision not to commence study.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Paroxysmal or Persistent AF, aged 18-80
- Presence of symptoms attributable to AF: EHRA 2 and above
- Clinical indication for LAAO procedure
- Own smartphone compatible with AliveCor device
Who cannot take part
- Previous LA ablation procedure
- Severe valvular disease
- Significant renal impairment (estimated glomerular filtration rate < 30)
- Non-AF arrhythmia (e.g., atypical flutter, focal atrial tachycardia, other narrow complex tachycardias)
- Severely impaired left ventricular function (ejection fraction < 35%)
- Permanent AF
- Body mass index ≥40
- Severely enlarged LA (\>50mm antero-posterior diameter)
- Pregnancy
- Significant frailty (Clinical Frailty Score < 5)
- Inability to provide informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Atrial fibrillation (AF) is the most common abnormal heart rhythm. It is also a leading cause of stroke, due to blood clots forming within an area called the 'left atrial appendage'. Usually, blood thinners (anticoagulants) are given to patients to reduce this risk. However, some patients are not able to take these medications due to a high bleeding risk. In this situation, these patients are sometimes offered a 'left atrial appendage occlusion' (LAAO) procedure - this is performed by inserting wires through the veins in the groin into the heart, then deploying a device which blocks the appendage, thus stopping blood clots from forming. There is increasing interest within our professional community of combining this procedure with another, called 'catheter ablation', which is performed to improve the symptoms of AF. This procedure uses similar access to the heart, but is not often performed in the same sitting - and often not performed at all in this patient group as they are felt to be at higher risk of complications due to bleeding or clotting. Pulsed Field Ablation (PFA) is a new technology which significantly improves safety of ablation. In this randomised controlled trial, patients referred for LAAO will be randomised to receive LAAO+PFA (intervention) or LAAO alone (control). Patients will be blinded to treatment received, which allows thorough assessment of the benefit of ablation.
The 2 groups in the trial
- Left atrial appendage occlusion aloneExisting treatment, for comparison
Left atrial appendage occlusions with the Watchman device (Boston Scientific)
Treatment: Left atrial appendage occlusion
- Combined left atrial appendage occlusion and pulsed field ablation of atrial fibrillationTreatment being tested
Left atrial appendage occlusion with the Watchman device (Boston Scientific) and catheter ablation of atrial fibrillation with the FaraPulse system (Boston Scientific)
Treatment: Catheter ablation of atrial fibrillation using Pulsed Field Ablation and Left atrial appendage occlusion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 July 2024